ALK and anaplastic large cell lymphoma: It concluded that ALK inhibitors should be accessible to children with anaplastic large cell lymphoma and inflammatory myofibroblastic tumor and that there was a deficiency of clinical trials and regulatory submissions: their submission was strongly encouraged.